Farmaindustria reinforces the collaboration to promote clinical research in Spain
Meeting with hospital pharmacists to exchange knowledge and experience between industry and professionals to promote trials
It was agreed to establish a mixed working group to continue the dialogue and continue to improve the quality of clinical studies.
Source: www.farmaindustria.es
Farmaindustria held this Wednesday at the Royal National Academy of Pharmacy (RANF), in Madrid, the Meeting of Understanding The role of the Hospital Pharmacy in Clinical Trials, which aimed at the exchange of experience and knowledge between promoters and these health professionals with The ultimate goal of continuing to make progress in improving the quantity and quality of clinical trials carried out in Spain, and in which pharmacists also play a relevant role.
Almost a hundred people, including hospital pharmacists and representatives of pharmaceutical companies, participated in the forum, which highlighted the need to improve aspects in terms of, inter alia, communication between promoters and pharmacists, reception of medications, training and training of these professionals, custody, dispensing and re-labeling of medications used in clinical trials or the return and destruction of such drugs.
This meeting was a continuation of similar ones with doctors, researchers and other health officials involved in clinical research, and in particular the Workshop of excellence in clinical trials, organized by Farmaindustria last July, in which the different links of the clinical trial were treated and where the need to deepen the dialogue with hospital pharmacists became evident.
As a conclusion to the forum held on Wednesday, it was agreed to establish a mixed working group between representatives of the trial promoters and hospital pharmacists to deepen and advance the issues raised, as well as to respond to the scientific and regulatory requirements of the new designs of clinical trials.
Spain already participates in 1 of every 3 trials in the EU
The RANF Forum, therefore, responds to Pharmaindustria’s interest in continuing to contribute to Spain being one of the leading clinical research countries in Europe and the world. It should be remembered that Spanish centers are already participating in one of every three clinical trials that are carried out in the continent and that for some multinationals Spain is the first country in the European Union after the United States to invest in trials.
A key to this progress, as the director of the Spanish Agency for Medicines and Health Products, María Jesús Lamas, explained at the meeting is that Spain was the first Member State to transpose the European regulation of clinical trials (RD 1090/2015 ), which has served as a catalyst to simplify and harmonize these studies, reduce time to start-up or increase studies in early stages (the most complex).
This sensitivity of the Administration has added to the high scientific level of health professionals, the excellence of hospitals, the growing involvement of patients and the confidence of the pharmaceutical industry in our country, in its professionals and in its facilities.
The meeting between professionals in the sector dealt with issues that Distefar knows firsthand how to facilitate the management of clinical trials as well as facilitate the participation of patients.
